Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

With a market cap of $799.5 billion, Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading global ...

Eli Lilly & Co. said it expects to generate adjusted 2025 profit of $22.50 a share to $24 a share in 2025. That compares to the FactSet consensus estimate of $22.76 a share for 2025. Lilly’s 2025 ...

Analysts expect the Indianapolis, Indiana-based company to report quarterly earnings at $5.08 per share, up from $2.49 per ...

Black-owned brands got a foot in the door through accelerator programs at big retailers like Target and Amazon. Now they ...

American depositary receipts (ADRs) of Novo Nordisk (NVO) jumped over 4% in pre-market trading this morning after reporting a healthy sales ...

LLY is reporting earnings tomorrow and the options market predicts major moves. PFP system shows bullish positioning and option flows for potential $900 target.

MORGANTOWN — West Virginia University is shutting down its Division of Diversity, Equity and Inclusion following Gov. Patrick ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

NEW YORK (AP) — Target's rollback on diversity ... receives support through the AP’s collaboration with The Conversation US, ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

Lilly said the U.S. could tackle that issue as part of the CUSMA review. Geist said another target could be Canada’s Online News Act, which compels tech companies to enter into agreements with news ...